Welcome
Support Centre
11 February 2012 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
HYpertension in the Very Elderly Trial
Source of recordUK Trials
ISRCTNISRCTN14031168
Date ISRCTN assigned18/11/2001
Local reference number(s)RG/97010
Public titleHYpertension in the Very Elderly Trial
Scientific title
AcronymHYVET
Disease/condition/study domainHypertension
Study hypothesisTo assess the benefits of treating very elderly patients with hypertension.
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration.
Countries of trialUnited Kingdom
Participants - inclusion criteria1. People 80 years old and above
2. Sustained systolic pressure 160 - 199 mmHg and diastolic (phase V) pressure 90 - 109 mmHg
3. No evidence of renal failure or co-morbidity requiring anti-hypertensive treatment
Participants - exclusion criteriaDoes not comply with above inclusion criteria.
Patient information material
Anticipated start date01/01/2001
Anticipated end date31/12/2009
Status of trialOngoing
Target number of participants2100
InterventionsTwo treatment groups:
1. Placebo
2. Indapamide Sustained Release (SR) 1.5 mg plus perindopril 2 - 4 mg if required.

Goal: diastolic blood pressure less than 80 mmHg with systolic pressure less than 150 mmHg.

The patients are followed-up both according to clinical need and every 3 months in the first year and every 6 months thereafter.
Primary outcome measure(s)Stroke events (fatal and non-fatal).
Secondary outcome measure(s)1. Total mortality
2. Cardiovascular mortality
3. Cardiac mortality
4. Stroke mortality
5. Skeletal fracture
Publications1. Main trial protocol in http://www.ncbi.nlm.nih.gov/pubmed/11302283
2. Sub-study protocol in http://www.ncbi.nlm.nih.gov/pubmed/17177983
Sources of funding1. British Heart Foundation (UK) (ref: RG/97010)
2. Institut de Recherches Internationales Servier (France)
Sponsor nameBritish Heart Foundation (UK)
Sponsor details14 Fitzhardinge Street
London
United Kingdom
W1H 6DH
Sponsor telephone+44 (0)20 7935 0185
Sponsor fax+44 (0)20 7486 5820
Sponsor emailresearch@bhf.org.uk
Sponsor websitehttp://www.bhf.org.uk/
Contact nameProfessor CJ Bulpitt
Contact detailsCare of the Elderly
Division of Medicine
ICSM at Hammersmith Hospital
Du Cane Road
London
United Kingdom
W12 0NN
Contact telephone+44 (0)20 8383 3959
Contact fax+44 (0)20 8743 0798
Contact emailc.bulpitt@ic.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN14031168
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central